Inovalon Data Powers New Insights on Diverse Healthcare Populations

Rhea-AI Summary

Inovalon (Nasdaq: INOV) announced the presentation of new data-driven research at various significant healthcare conferences. This research is powered by Inovalon’s MORE² Registry^®, which contains extensive real-world data on over 332 million patients. The MORE² Registry^® will be highlighted at meetings such as the AMCP Managed Care & Specialty Pharmacy Annual Meeting and the ISPOR Annual Meeting, focusing on healthcare costs and outcomes. This initiative aims to provide stakeholders with deeper insights into healthcare utilization and economic impacts.

Positive

• Presentation at multiple high-profile healthcare conferences enhances visibility and credibility.
• Access to extensive real-world data with over 332 million patients can drive meaningful healthcare insights.
• Collaboration with Avalere Health provides strategic research advantages.

Negative

• None.

Data-Driven Research Presented at Academy of Managed Care Pharmacy (AMCP), ISPOR Annual Meeting and Key Spring Conferences Powered by Inovalon’s MORE2 Registry® Dataset

BOWIE, Md., March 31, 2021 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced new research to be presented across all major healthcare coverage populations powered by its large-scale, real-world Medical Outcomes Research for Effectiveness and Economics Registry (MORE² Registry^®).

Inovalon’s MORE² Registry^®, one of the nation’s largest and most comprehensive healthcare datasets, will be featured in research presented at: the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, the American Thoracic Society (ATS) International Conference, the American College of Cardiology’s 70th Annual Scientific Session, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, Digestive Disease Week 2021, and the AcademyHealth Annual Research Meeting.

“The research that is being presented at these conferences showcases the capabilities and depth of the MORE² Registry^®,” said John E. Linnehan, practice director of Health Economics & Advanced Analytics in Inovalon’s Life Sciences & Advisory Services business. “The MORE² Registry^® provides an unparalleled view of the healthcare marketplace, giving all healthcare stakeholders practical solutions to understand, influence, and thrive in today’s environment.”

Inovalon’s MORE² Registry^® dataset is one of the nation’s largest primary source, longitudinally matched datasets containing real-world medical, pharmacy, laboratory, demographic, and clinical data on more than 332 million unique patients and 61 billion medical events across Medicare fee-for-service, Medicare Part D, Medicare Advantage, managed Medicaid, and commercially insured populations. Ongoing analysis of the MORE² Registry^® dataset powers highly valuable insights into important healthcare issues; machine learning, deep learning, and artificial intelligence algorithm development and training for Modules of the Inovalon ONE^® Platform; and the real-time decision support, care, quality, outcomes and economic improvements of healthcare empowered through Inovalon’s solutions.

This research, spanning multiple high-impact healthcare industry challenges, was conducted by Avalere Health, an Inovalon company specializing in data-driven healthcare research and strategic advisory services, in partnership with its clients.

Research to be Presented

AMCP Managed Care & Specialty Pharmacy Annual Meeting from April 13-14, 2021

• Mortality, Healthcare Burden and Costs of Clostridioides Difficile Infections and Recurrences in the Medicare Population
• Relationship of COPD Exacerbation Burden on Subsequent Healthcare Costs in a Medicare FFS Claims Analysis
• Direct Healthcare Resource Utilization and Cost in Managed Care Members with Non-Dialysis Dependent Chronic Kidney Disease, with and Without Severe Anemia
• Real-World Healthcare Utilization, Costs, and Overall Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Ruxolitinib Exposed vs. Unexposed

ATS International Conference from May 14-19, 2021

• Does Baseline Exacerbation History in COPD Predict Future Exacerbation Frequency? Real-World Insights from Multiple U.S. Insurers
• Pneumonia Burden and Exacerbations: A Large Real-World Evaluation of Events and Risks Among COPD Patients in the U.S.

American College of Cardiology’s 70th Annual Scientific Session from May 15-17, 2021

• Part D Out of Pocket Payments in Medicare Beneficiaries with Heart Failure with Reduced Ejection Fraction
  

Virtual ISPOR 2021 from May 15-17, 2021

• Healthcare Utilization, Cost, and Quality Among High-Need, High-Cost Medicare Beneficiaries in Medicare Fee-for-Service vs. Medicare Advantage
• Incident Costs of Dialysis Initiation Among Medicare Beneficiaries with Advanced Chronic Kidney Disease
• Characteristics, Cost, and Healthcare Resource Use in a Population of Medicare Fee-for-Service Patients with Chronic Obstructive Pulmonary Disease (COPD) Who also Experience Pneumonia
  

Digestive Disease Week 2021 from May 21-23, 2021

• A Real-World Comparison of Mortality, Healthcare Resource Utilization, and Cost Among Medicare Beneficiaries with Clostridioides Difficile Infection with and Without Sepsis
  

AcademyHealth Annual Research Meeting from June 14-17, 2021

• Healthcare Utilization, Cost and Quality Among High-Need Medicare Beneficiaries in Medicare Fee-for-Service vs. Medicare Advantage
  

About Inovalon

Inovalon is a leading provider of cloud-based platforms empowering data-driven healthcare. Through the Inovalon ONE^® Platform, Inovalon brings to the marketplace a national-scale capability to interconnect with the healthcare ecosystem, aggregate and analyze data in real time, and empower the application of resulting insights to drive meaningful impact at the point of care. Leveraging its Platform, unparalleled proprietary datasets, and industry-leading subject matter expertise, Inovalon enables better care, efficiency, and financial performance across the healthcare ecosystem. From health plans and provider organizations, to pharmaceutical, medical device, and diagnostics companies, Inovalon’s unique achievement of value is delivered through the effective progression of “Turning Data into Insight, and Insight into Action^®.” Supporting thousands of clients, including all 25 of the top 25 U.S. health plans, 22 of the top 25 global pharma companies, 19 of the top 25 U.S. healthcare provider systems, and many of the leading pharmacy organizations, device manufacturers, and other healthcare industry constituents, Inovalon’s technology platforms and analytics are informed by data pertaining to more than one million physicians, 574,000 clinical facilities, 332 million Americans, and 61 billion medical events. For more information, visit www.inovalon.com.

Contact:

Kim E. Collins
Senior Vice President, Corporate Communications
kcollins@inovalon.com
301-809-4000 x1473

Hulus Alpay
Vice President, Investor Relations
halpay@inovalon.com
301-809-4000 x1237

FAQ

What research is Inovalon presenting at the AMCP Annual Meeting?

Inovalon is presenting research on healthcare burden and costs related to Clostridioides difficile infections in the Medicare population.

How many patients' data does the MORE² Registry^® include?

The MORE² Registry^® includes data on over 332 million unique patients.

What is the significance of the MORE² Registry^® for healthcare?

The MORE² Registry^® provides unparalleled insights into healthcare marketplace dynamics and helps improve care outcomes.

Which conferences will feature Inovalon's research?

Inovalon's research will be featured at several conferences, including the AMCP, ATS International Conference, and ISPOR Annual Meeting.

Who conducted the research presented by Inovalon?

The research was conducted by Avalere Health, an Inovalon company specializing in data-driven healthcare research.